JLINX: A New Company Incubation Model Located at the Janssen Campus in Belgium




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: JLINX: A New Company Incubation Model Located at the Janssen Campus in Belgium
Released on: December 22, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Johnson & Johnson Innovation Launches JLINX: A New Company Incubation Model Located at the Janssen Campus in Belgium Johnson & Johnson Innovation, JLINX will offer scientists and entrepreneurs access to venture funding, R&D expertise and state-of-the-art facilities JLINX is designed to accelerate early-stage transformative innovation, including an emphasis on the human microbiome as well as broader life-science research
  • Summary
  • Participants
  • Company
Johnson & Johnson Innovation Launches JLINX: A New Company Incubation Model Located at the Janssen Campus in Belgium Johnson & Johnson Innovation, JLINX will offer scientists and entrepreneurs access to venture funding, R&D expertise and state-of-the-art facilities JLINX is designed to accelerate early-stage transformative innovation, including an emphasis on the human microbiome as well as broader life-science research
Experienced life science executive with a PhD in Pharmaceutical Sciences. Driven by a passion to develop impactful healthcare solutions through novel ventures and collaborative models. More than 20 years of experience in life science innovation, entrepreneurship and building bridges between stakeholders. Started my professional career as a founding director at the biotech start-ups Tibotec and Virco and continued my career in different regional and global senior leadership positions within Johnson & Johnson. Here, I made significant personal contributions to Tibotec’s anti-infectives portfolio (Prezista, Intelence, Edurant, Olysio, Sirturo) and Virco’s HIV-resistance testing platform. Collectively, Tibotec and Virco positively impacted the lives of hundreds of thousands of patients turning HIV/AIDS into a manageable disease, and Hepatitis C and MDR-Tuberculosis into curable diseases. It is my vision that transformational healthcare solutions of the future will only emerge and progress through novel collaborative ventures in a complex life science ecosystem. Therefore I joined the J&J Innovation Centre in London further building on my unique experience of having been in both a successful small biotech and big pharma environment. Here I also expanded my network of contacts and relationships with numerous stakeholders in all top life science regions across Europe. Moving forward success in Life Science and Healthcare Innovation will critically depend on the capability, and competencies of individuals and organizations to effectively close the wide gap between different stakeholders, or to develop novel alliances at the interface between all of them (Academia, Investors, SME’s, Technology Providers, Regulators, Big Pharma, …). Through natural curiosity I am always open to learn more about opportunities seeking to develop creative and transformational healthcare solutions through novel ventures or start-ups.
Johnson & Johnson (J&J)
Johnson & Johnson is a global American pharmaceutical, medical devices and consumer packaged goods manufacturer founded in 1886. Its common stock is a component of the Dow Jones Industrial Average and the company is listed among the Fortune 500. Johnson & Johnson is known for its corporate reputation, consistently ranking at the top of Harris Interactive's National Corporate Reputation Survey, ranking as the world's most respected company by Barron's Magazine, and was the first corporation awarded the Benjamin Franklin Award for Public Diplomacy by the U.S. State Department for its funding of international education programs.